Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Hans F. A. Vasen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2682-2603; OpenAlex author ID A5010756339. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
65
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 4 papers

Papers 27

  1. The odyssee from surveillance to the detection of pancreatic cancer, total pancreatectomy, and its impact on life. insights from a p16-Leiden pathogenic varian… First author DOI 10.1007/s10689-024-00385-0↗
  2. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions. Co-author DOI 10.1007/s10689-024-00394-z↗
  3. Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue. Co-author DOI 10.1007/s10689-024-00404-0↗
  4. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  5. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  6. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals. Co-author DOI 10.1016/j.pan.2022.03.021↗
  7. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗
  8. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. Co-author DOI 10.1136/jmedgenet-2019-106562↗
  9. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. Co-author DOI 10.3390/ijms22052655↗
  10. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  11. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  12. Screening of Individuals at High Risk for Pancreatic Cancer Co-author DOI 10.1016/j.cgh.2019.03.023↗
  13. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillanc… Co-author DOI 10.1016/j.hpb.2019.02.013↗
  14. High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers. Last author DOI 10.1158/1940-6207.capr-18-0035↗
  15. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Last author DOI 10.1007/s10689-016-9915-3↗
  16. The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer Co-author DOI 10.1007/s10689-017-0066-y↗
  17. Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Co-author DOI 10.1136/jclinpath-2016-203928↗
  18. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Last author DOI 10.1016/j.tranon.2016.03.003↗
  19. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  20. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  21. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques. Co-author DOI 10.1007/s00432-014-1812-2↗
  22. Familial Pancreatic Cancer: To Screen or not to Screen? Co-author DOI 10.1016/j.ebiom.2015.12.014↗
  23. Limited resection of pancreatic cancer in high-risk patients can result in a second primary. Last author DOI 10.1136/gutjnl-2015-309568↗
  24. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study. Co-author DOI 10.1186/s13104-015-1235-4↗
  25. Detection of pancreatic cancer using serum protein profiling. Co-author DOI 10.1111/hpb.12017↗
  26. Variation in precursor lesions of pancreatic cancer among high-risk groups. Co-author DOI 10.1158/1078-0432.ccr-12-2730↗
  27. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Co-author DOI 10.1053/j.gastro.2010.11.048↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bert A. Bonsing · 18 shared papers, 2011–2024 · strength 1.60
  2. Martin N.J.M. Wasser · 11 shared papers, 2011–2024 · strength 1.08
  3. Monique Esther van Leerdam · 6 shared papers, 2021–2024 · strength 0.96
  4. Thomas P. Potjer · 10 shared papers, 2013–2024 · strength 0.87
  5. Bas Boekestijn · 5 shared papers, 2019–2024 · strength 0.80
  6. J. Sven D. Mieog · 5 shared papers, 2017–2024 · strength 0.76
  7. Jeanin Elise van Hooft · 5 shared papers, 2020–2024 · strength 0.62
  8. Detlef Klaus Bartsch · 8 shared papers, 2013–2020 · strength 0.60
  9. Derk C.F. Klatte · 4 shared papers, 2022–2024 · strength 0.58
  10. Isaura S. Ibrahim · 7 shared papers, 2016–2022 · strength 0.57
  11. Hans Morreau · 8 shared papers, 2011–2023 · strength 0.57
  12. Marcia Irene Canto · 3 shared papers, 2020–2024 · strength 0.52
  13. Michael Goggins · 3 shared papers, 2020–2024 · strength 0.52
  14. Rob A.E.M. Tollenaar · 7 shared papers, 2011–2022 · strength 0.49
  15. Amarensia Spruitenburg · 1 shared paper, 2024 · strength 0.46
  16. Alfredo Carrato · 5 shared papers, 2016–2020 · strength 0.40
  17. Yuri E. M. van der Burgt · 5 shared papers, 2013–2022 · strength 0.40
  18. Wilma E. Mesker · 5 shared papers, 2013–2022 · strength 0.40
  19. Kasper A. Overbeek · 4 shared papers, 2020–2022 · strength 0.40
  20. Marco J. Bruno · 4 shared papers, 2020–2022 · strength 0.40
  21. Djuna L. Cahen · 4 shared papers, 2020–2022 · strength 0.40
  22. Wouter H. de Vos tot Nederveen Cappel · 5 shared papers, 2011–2019 · strength 0.26
  23. Manfred Wuhrer · 2 shared papers, 2021–2022 · strength 0.26
  24. Randa G. Hanna-Sawires · 2 shared papers, 2021–2022 · strength 0.26
  25. Frederik Jan Hes · 4 shared papers, 2011–2021 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.